B-Cell Lymphoma

The FDA granted accelerated approval to epcoritamab-bysp for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.

Ten of 11 patients with relapsed or refractory B-cell lymphoma achieved objective response to an investigational dual-target chimeric antigen receptor T-cell therapy, according to study results.

The FDA approved polatuzumab vedotin-piiq in combination with rituximab, cyclophosphamide, doxorubicin and prednisone as first-line therapy for patients with certain types of B-cell lymphoma.

Physicians recommended chimeric antigen receptor T-cell therapy more frequently than any other regimen for third-line treatment of relapsed or refractory diffuse large B-cell lymphoma, survey results showed.

Axicabtagene ciloleucel significantly extended survival compared with historic standard of care in a curative setting for adults with previously untreated relapsed or refractory large B-cell lymphoma, according to the agent’s manufacturer.

Polatuzumab vedotin-piiq exhibited a favorable risk-benefit profile as first-line treatment for patients with large B-cell lymphoma, according to an 11-2 vote of the FDA’s Oncologic Drugs Advisory Committee.

Automatic calcium scoring with nongated chest CT was prognostic of major adverse and cardiotoxicity-related CV events in patients with large B-cell lymphoma undergoing anthracycline-based chemotherapy, researchers reported.

A remote dietary intervention was feasible and reduced chronic fatigue among lymphoma survivors, according to researchers.

NEW ORLEANS — Patients older than 80 years of age with diffuse large B-cell lymphoma more than tripled their overall survival when receiving at least six cycles of chemotherapy.

In this edition, cancer and COVID-19 increase risk for thromboembolism, glofitamab shows curative potential in lymphoma, efgartigimod improves platelet counts, and more.